Each antihypertensive step-up in early severe pre-eclampsia tracks rising maternal risk

The edition in brief

In 396 women managed expectantly for pre-eclampsia with severe features between 23 and 33 weeks at one US referral centre, each additional oral antihypertensive dose escalation was associated with a 4.2 percentage point absolute rise in a composite of serious maternal outcomes (95% CI 2.0 to 6.5). Three escalations carried an adjusted relative risk of 4.07 and four or more 5.20 against none; repeated intravenous pushes showed the same gradient. This is a retrospective association, not evidence that escalating causes harm — the likelier reading is that the treatment trajectory mirrors worsening disease, and is worth tracking as a signal when reviewing whether to continue expectant management. A systematic review of 18 randomised trials found continuous or extended-cycle combined pills as effective as 21/7 or 24/4 cycles (unintended pregnancy OR 0.79, 0.41 to 1.52), with fewer total bleeding days in some trials but more unscheduled bleeding. A prospective study of 14,114 pregnant women in North America and Europe found 1.7% were HPA-1b/1b; of 19 higher-risk women followed, 2 formed anti-HPA-1a antibodies by 10 weeks postpartum — a small denominator, but useful counselling data for a rare condition. The pearl covers the time-critical treatment of severe-range blood pressure. The practice changer: an ACOG Clinical Practice Update, published 25 August, supports complete bilateral salpingectomy at obstetric and gynaecological surgery for ovarian cancer prevention and extends the offer to suitable non-gynaecological abdominopelvic operations.